2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report

EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report - PDF(Abstract)

Back to course

Pdf Summary

The study presented a case report of a patient with metastatic non-small cell lung cancer (NSCLC) and symptomatic brain metastases. The patient had previously received treatment with osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), but experienced disease progression. The patient was then treated with a combination of aumolertinib, another third-generation EGFR-TKI, and stereotactic body radiation therapy (SBRT). This treatment approach resulted in an improvement in neurological symptoms and a prolongation of survival. The patient experienced stable disease for a period of 12.1 months and had an overall survival of 20.6 months. The case highlights the potential efficacy of aumolertinib in EGFR-mutated NSCLC, particularly in patients with symptomatic brain metastases.

Asset Subtitle

Xiaojuan Zhang

Meta Tag

Speaker Xiaojuan Zhang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

metastatic non-small cell lung cancer

symptomatic brain metastases

osimertinib

third-generation EGFR tyrosine kinase inhibitor

disease progression

aumolertinib

stereotactic body radiation therapy

neurological symptoms

prolongation of survival

EGFR-mutated NSCLC